Order Center
 
Life Science

Antibodies
Automation
Cancer Research
Cell Culture
Cell Signaling and Neuroscience
Product Lines
Product Highlights
New Literature
Ion Channels
Key Resources
Cell Signaling Web Tools
New Products
PathFinder
Pathway Slides & Charts
Pharm. Action Table
Poster Gallery
Protocols
Search Tools
eHandbook
Custom Synthesis
Drug Discovery
Epigenetics
Functional Genomics and RNAi
Metabolomics
Molecular Biology
Neuroscience
Nutrition Research
Obesity Research
Peptides and Proteins
Plant Biotechnology
Proteomics and Protein Expr.
Stable Isotopes
Stem Cell Biology
Your Favorite Gene - Search
Life Science Innovations
PathFinder

 

Mechanism of Action of Selective Monoaminergic Reuptake Inhibitors. Figure B

Top Border
Left Border  Right Border
Left Corner Back Download Forward Sigma-Aldrich Right Corner

Mechanism of Action of Selective Monoaminergic Reuptake Inhibitors

During neurotransmission, monoamine neurotransmitters such as serotonin, dopamine or norepinephrine, are released into the synaptic cleft from storage vesicles present in the pre-synaptic neuron (Figure A). The neurotransmitters then bind to their respective receptors on the post-synaptic neuron, thereby transferring the signal. The actions of the neurotransmitters are terminated via their reuptake into the pre-synaptic neuron via specific transporter proteins following which the neurotransmitter is taken up into the vesicles for re-release. When a monoaminergic reuptake inhibitor is present (Figure B), it binds to the monoamine transporter and blocks the reuptake of the neurotransmitter whose levels increase in the synaptic cleft thereby enhancing neurotransmission.

Back to Top


Site Use Terms Terms and Conditions of Sale Privacy Business Development Contact Us
Copyrights © 2008 Sigma-Aldrich Co. All Rights Reserved.
Reproduction of any materials from the site is strictly forbidden without permission.
Sigma-Aldrich brand products are sold exclusively through Sigma-Aldrich, Inc.